1 / 11

Fee for Service Trends: A Look at Medicare Part B

Fee for Service Trends: A Look at Medicare Part B. Scott Reid, Pharm.D. Vice President Specialty Pharmacy Operations. National Medicare Prescription Drug Congress Nov. 1, 2005. Snapshot of Caremark Participation in Medicare. Medicare Part B provider since 1983 Home infusion: 1979-1996

guinevere
Download Presentation

Fee for Service Trends: A Look at Medicare Part B

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Fee for Service Trends: A Look at Medicare Part B Scott Reid, Pharm.D. Vice President Specialty Pharmacy Operations National Medicare Prescription Drug Congress Nov. 1, 2005

  2. Snapshot of Caremark Participation in Medicare • Medicare Part B provider since 1983 • Home infusion: 1979-1996 • Specialty pharmacy: current • Hemophilia • Oral oncology • AWP transition to average sale price (ASP) • Coordination of benefits • Competitive acquisition program: proposed • Office administered drugs • ASP + 6% • Part D: January 2006 • MRDD: September 2004 • PDP and pharmacy provider • AWP-% • Medication therapy management (MTM) *

  3. Home Infusion Therapy • Medicare Part B: prosthetic device / home medical equipment benefit • Payment available for drugs and supplies incident to the use of a pump: • Drug component • Administration/catheter care kit • Pump fee • AWP model provided adequate payment to cover product, professional services, ancillaries and services • Professional services of a pharmacist and nurses are not recognized under ASP, including: • Patient education/training • Medication management • Care management and coordination

  4. Home Infusion Therapy • Not all infusion therapy drugs covered under Medicare Part B • Under the Medicare Modernization Act, infused medications covered under Part B remain at 95% of average wholesale price (AWP) • Drugs not administered via an infusion pump are covered under Part D • Part D does not recognize or cover nondrug products, supplies and services, causing problems for infusion therapy providers where another benefit/policy does not exist • Final disposition of infusion products under further review

  5. Part B Pricing Reform: Pharmacy Provider • Physician services • ASP +6% • Increase in fees for existing procedure codes • Implemented new codes for previously unrecognized services / expenses • Alternative to buy and bill • Conversion to ASP + 6% does not recognize: • Professional services of a pharmacist • Care management • “Buried” costs for pharmacies • Pharmacies have no method to bill or receive payment for professional services of a pharmacist

  6. Part B Pricing Reform: Pharmacy Provider • Hemophilia payment methodology was amended to add an administration fee for each unit dispensed • Potential access issue due to pricing methodology • CMS has addressed this issue in part by covering a “dispensing / supply” fee for other Medicare Part B drugs: • Inhalation • Oral oncologics • Transplant • Dispensing fee to cover costs of service • Supply fee to cover higher costs of processing claims due to lack of online adjudication • CMS will continue to evaluate to assure adequacy of payment • Hospital outpatient prospective payment system: • July 2005: CMS proposes ASP +8% • Supported by hospital groups

  7. ASP and Today’s Pharmacy Marketplace • Pricing system / benchmark developed to provide more accurate reporting of drug prices to government and other payors • Weighted average of nonfederal sales from pharmaceutical manufacturers to wholesalers • Net of volume discounts, rebates, chargebacks and other benefits tied to sale of drug • Average is calculated across all classes of trade with exception of hospitals and government programs (Medicaid, 340B, federal supply schedule)

  8. ASP and Today’s Pharmacy Marketplace • Rebates, discounts and other price reductions are not available to all purchasers on an equal basis • Pricing to providers varies significantly • Reflects prices paid by wholesalers not by pharmacy providers • Rebates are not available to pharmacies • Does not reflect acquisition price, costs of acquisition and management of inventory of pharmacies • Professional services of pharmacists

  9. Competitive Acquisition Program • Alternative to physician buy and bill • Uses ASP as basis for payment with mark-up of 6% • ASP calculation crosses over several classes of trade • Lag time between current prices and when ASP is set • Quantity dispensed by pharmacy may not be quantity paid • Logistical issues between provider processes and physician / clinic practices • Does not contemplate unused/unadministered drug • Wholesale versus pharmacy model … or other? • Fails to account for real expenses of delivering and managing the program • Most potential providers are under water based on drug cost alone • Waiting for revised rules

  10. Medicare Part B and Part D • Coverage under Part B versus Part D • Immunosupressives: Organ transplants • Oral antiemetics: Adjunct to oncologics • Oral oncologics: drug is same as, precursor or metabolite of IV drug already covered • Inhalation drugs: nebulizer only inhalers under Part D • Parenteral drugs not administered via a pump covered under Part D • Medicare Replacement Drug Demonstration drugs • Further changes to be made after implementation after further review and analysis by CMS

  11. Summary • Need an effective and timely method for calculating ASP that more directly reflects the prices paid by pharmacies • Percent mark-up must recognize and cover total cost of providing medications and service • Benefit design and coverage must be appropriate for the service model and site of care • Impact on specialty pharmacy’s ability to continue to provide current services and optimize value to Medicare beneficiaries, health plans and physicians • Transition to ASP model will need to recognize and pay for professional services of a pharmacist • Adoption of new current procedural terminology codes for MTM services and its application under a drug benefit

More Related